National Cancer Institute; Notice of Closed Meetings, 21526-21527 [2024-06548]

Download as PDF 21526 Federal Register / Vol. 89, No. 61 / Thursday, March 28, 2024 / Notices Bethesda, MD 20852, 301–443–6480, sweiss@ nida.nih.gov. Contact Person: Jeanette Marketon, Ph.D., PMP Director, Office of Extramural Policy. Division of Extramural Research, Office of Extramural Policy, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09C71, 11601 Landsdown Street, Bethesda, MD 20852, 301–443–5239, jeanette.marketon@nih.gov. Authority: Reconnecting Homeless Youth Act of 2008 (Pub. L. 110–378) through Fiscal Year (FY) 2013 and reauthorized by the Juvenile Justice Reform Act through FY 2019. Mary C. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2024–06546 Filed 3–27–24; 8:45 am] BILLING CODE 4184–04–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting ddrumheller on DSK120RN23PROD with NOTICES1 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse. This will be a hybrid meeting held inperson and virtually and will be open to the public, as indicated below, with attendance limited to space available. Individuals who plan to attend inperson or view the virtual meeting and need special assistance such as sign language interpretation or other reasonable accommodations, should notify Dr. Jeanette Marketon via email at jeanette.marketon@nih.gov five days in advance of the meeting. The open session of the meeting can be accessed from the NIH Videocast at the following link: https://videocast.nih.gov/. A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse. Date: May 7, 2024. Closed: 10:30 a.m. to 11:45 a.m. Agenda: To review and evaluate grant applications. Open: 12:45 p.m. to 5:00 p.m. Agenda: Presentations and other business of the Council. Place: Neuroscience Center, Conference Room 1155/1145, National Institutes of Health, 6001 Executive Boulevard, Rockville, MD 20852 (Hybrid Meeting). Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown Street, VerDate Sep<11>2014 20:27 Mar 27, 2024 Jkt 262001 Any interested person may file written comments with the committee by forwarding the statement to Dr. Jeanette Marketon via email at jeanette.marketon@nih.gov. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at https://www.nih.gov/ about-nih/visitor-information/campusaccess-security for entrance into oncampus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: www.drugabuse.gov/NACDA/ NACDAHome.html, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: March 25, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–06612 Filed 3–27–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE (P50) Review SEP–II. Date: May 15–16, 2024. Time: 9:30 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Anita T. Tandle, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850, 240–276–5085, tandlea@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–10: NCI Clinical and Translational Cancer Research. Date: May 15, 2024. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W104, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: David G. Ransom, Ph.D., Chief, Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W104, Rockville, Maryland 20850, 240–276–6351, david.ransom@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE, U54). Date: May 16, 2024. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W108, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Clifford W. Schweinfest, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W108, Rockville, Maryland 20850, 240–276–6343, schweinfestcw@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Diet, Lipid Metabolism, and Cancer. Date: May 16, 2024. Time: 9:30 a.m. to 2:00 p.m. E:\FR\FM\28MRN1.SGM 28MRN1 ddrumheller on DSK120RN23PROD with NOTICES1 Federal Register / Vol. 89, No. 61 / Thursday, March 28, 2024 / Notices Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Shree Ram Singh, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850, 240–672–6175, singhshr@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–7: NCI Clinical and Translational Cancer Research. Date: May 17, 2024. Time: 10:00 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Saejeong J. Kim, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850, 240–276–7684, saejeong.kim@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–1: NCI Clinical and Translational Cancer Research. Date: May 23, 2024. Time: 9:30 a.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Shree Ram Singh, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850, 240–672–6175, singhshr@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel SEP–3; NCI Clinical and Translational Cancer Research. Date: June 5, 2024. Time: 9:30 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Prashant Sharma, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850, 240–275–6351, prashant.sharma@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, VerDate Sep<11>2014 20:27 Mar 27, 2024 Jkt 262001 Cancer Control, National Institutes of Health, HHS) Dated: March 22, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. 21527 Dated: March 25, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–06618 Filed 3–27–24; 8:45 am] BILLING CODE 4140–01–P [FR Doc. 2024–06548 Filed 3–27–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HOMELAND SECURITY Coast Guard National Institutes of Health [Docket No. USCG–2024–0233] National Institute on Drug Abuse; Notice of Closed Meeting Information Collection Request to Office of Management and Budget; OMB Control Number: 1625–0011 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, NIDA. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute on Drug Abuse, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIDA. Date: May 7, 2024. Closed: 9:00 a.m. to 5:30 p.m. Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Date: May 8, 2024. Closed: 9:15 a.m. to 3:55 p.m. Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Date: May 9, 2024. Closed: 9:30 a.m. to 3:20 p.m. Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Place: National Institute on Drug Abuse, NIH, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224 (Virtual Meeting). Contact Person: Megan E. Bollinger, M.S., Management Analyst, Office of the Scientific Director, National Institute on Drug Abuse, 251 Bayview Boulevard, Suite 200, Baltimore, MD 21224, (443) 740–2466, Megan.Bollinger@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 Coast Guard, DHS. Sixty-Day notice requesting comments. AGENCY: ACTION: In compliance with the Paperwork Reduction Act of 1995, the U.S. Coast Guard intends to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting an extension of its approval for the following collection of information: 1625–0011, Applications for Private Aids to Navigation and for Class I Private Aids to Navigation on Artificial Islands and Fixed Structures; without change. Our ICR describes the information we seek to collect from the public. Before submitting this ICR to OIRA, the Coast Guard is inviting comments as described below. DATES: Comments must reach the Coast Guard on or before May 28, 2024. ADDRESSES: You may submit comments identified by Coast Guard docket number [USCG–2024–0233] to the Coast Guard using the Federal eRulemaking Portal at https://www.regulations.gov. See the ‘‘Public participation and request for comments’’ portion of the SUPPLEMENTARY INFORMATION section for further instructions on submitting comments. A copy of the ICR is available through the docket on the internet at https:// www.regulations.gov. Additionally, copies are available from: Commandant (CG–6P), Attn: Paperwork Reduction Act Manager, U.S. Coast Guard, 2703 Martin Luther King Jr. Ave. SE, Stop 7710, Washington, DC 20593–7710. FOR FURTHER INFORMATION CONTACT: A.L. Craig, Office of Privacy Management, telephone 202–475–3528, fax 202–372– 8405, or email hqs-dg-m-cg-61-pii@ uscg.mil for questions on these documents. SUPPLEMENTARY INFORMATION: SUMMARY: E:\FR\FM\28MRN1.SGM 28MRN1

Agencies

[Federal Register Volume 89, Number 61 (Thursday, March 28, 2024)]
[Notices]
[Pages 21526-21527]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06548]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; NCI SPORE (P50) Review SEP-II.
    Date: May 15-16, 2024.
    Time: 9:30 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute Shady Grove, 9609 Medical 
Center Drive, Room 7W248, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Anita T. Tandle, Ph.D., Scientific Review 
Officer, Research Programs Review Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W248, Rockville, Maryland 20850, 240-276-5085, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; SEP-10: NCI Clinical and Translational Cancer Research.
    Date: May 15, 2024.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute Shady Grove, 9609 Medical 
Center Drive, Room 7W104, Rockville, Maryland 20850 (Virtual 
Meeting).
    Contact Person: David G. Ransom, Ph.D., Chief, Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W104, Rockville, Maryland 20850, 240-276-6351, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Comprehensive Partnerships to Advance Cancer Health Equity 
(CPACHE, U54).
    Date: May 16, 2024.
    Time: 9:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute Shady Grove, 9609 Medical 
Center Drive, Room 7W108, Rockville, Maryland 20850 (Virtual 
Meeting).
    Contact Person: Clifford W. Schweinfest, Ph.D., Scientific 
Review Officer, Special Review Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W108, Rockville, Maryland 20850, 240-276-6343, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Diet, Lipid Metabolism, and Cancer.
    Date: May 16, 2024.
    Time: 9:30 a.m. to 2:00 p.m.

[[Page 21527]]

    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W248, Rockville, Maryland 20850 (Virtual 
Meeting).
    Contact Person: Shree Ram Singh, Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W248, Rockville, Maryland 20850, 240-672-6175, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; SEP-7: NCI Clinical and Translational Cancer Research.
    Date: May 17, 2024.
    Time: 10:00 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W640, Rockville, Maryland 20850 (Virtual 
Meeting).
    Contact Person: Saejeong J. Kim, Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W640, Rockville, Maryland 20850, 240-276-7684, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; SEP-1: NCI Clinical and Translational Cancer Research.
    Date: May 23, 2024.
    Time: 9:30 a.m. to 3:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W248, Rockville, Maryland 20850 (Virtual 
Meeting).
    Contact Person: Shree Ram Singh, Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W248, Rockville, Maryland 20850, 240-672-6175, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel SEP-3; NCI Clinical and Translational Cancer Research.
    Date: June 5, 2024.
    Time: 9:30 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute Shady Grove, 9609 Medical 
Center Drive, Room 7W612, Rockville, Maryland 20850 (Virtual 
Meeting).
    Contact Person: Prashant Sharma, Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W612, Rockville, Maryland 20850, 240-275-6351, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: March 22, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-06548 Filed 3-27-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.